FIRST REPORTED CASE OF ANTI-AMPAR ENCEPHALITIS WITH CONCURRENT MYASTHENIA GRAVIS AND THYMOMA IN VIETNAM
Main Article Content
Abstract
Autoimmune encephalitis associated with antibodies against the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor is a rare subtype of autoimmune encephalitis. We report the clinical presentation, laboratory findings, and treatment outcomes of the first documented Vietnamese case of anti-AMPAR autoimmune encephalitis occurring concurrently with myasthenia gravis and thymoma. The patient was a 42-year-old woman with a history of myasthenia gravis who was admitted with characteristic symptoms of limbic encephalitis, including memory impairment and confusion. Anti-AMPAR antibodies were detected in both serum and cerebrospinal fluid using indirect immunofluorescence. Chest computed tomography revealed an anterior mediastinal mass. The patient was treated with high-dose methylprednisolone and five cycles of plasma exchange. She exhibited transient improvement in consciousness and was scheduled for surgical resection and histopathological evaluation of the mediastinal mass; however, due to the high surgical risk, the procedure was not performed.
Article Details
Keywords
autoimmune encephalitis, AMPA receptor, thymoma, myasthenia gravis
References
2. Guasp, M., et al., Thymoma and Autoimmune Encephalitis. Neurology Neuroimmunology, 2021. 8(5): p. e1053. doi: 10.1212/NXI.0000000000001053
3. Tannemaat, M.R., M.G. Huijbers, and J. Verschuuren, Myasthenia gravis-Pathophysiology, diagnosis, and treatment. Handb Clin Neurol, 2024. 200: p. 283–305. doi: 10.1016/B978-0-12-823912-4.00026-8
4. Lai, M., et al., AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol, 2009. 65(4): p. 424–34. doi: 10.1002/ana.21589.
5. Byun, J.I., et al., Prevalence of antineuronal antibodies in patients with encephalopathy of unknown etiology: Data from a nationwide registry in Korea. J Neuroimmunol, 2016. 293: p. 34–38. doi: 10.1016/j.jneuroim.2016.02.002
6. Höftberger, R., et al., Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients. Neurology, 2015. 84(24): p. 2403–12. doi: 10.1212/WNL.0000000000001682
7. Graus, F., et al., A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol, 2016. 15(4): p. 391–404. doi: 10.1016/S1474-4422(15)00401-9
8. Evoli, A. and E. Lancaster, Paraneoplastic disorders in thymoma patients. J Thorac Oncol, 2014. 9(9 Suppl 2): p. S143–7. doi: 10.1097/JTO.0000000000000300
9. Omi, T., et al., Clinical Relapse of Anti-AMPAR Encephalitis Associated with Recurrence of Thymoma. Intern Med, 2018. 57(7): p. 1011–1013. doi: 10.2169/internalmedicine.9682-17
10. Tan, S., et al., Anti-α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Receptor Antibody Encephalitis in an Immunosuppressed Patient With Myasthenia Gravis Post-thymoma Treatment. Cureus, 2024. 16(6): p. e63239. doi: 10.7759/cureus.63239.
11. Dalmau, J. and A. Vincent, Do we need to measure specific antibodies in patients with limbic encephalitis? Neurology, 2017. 88(6): p. 508–509. doi: 10.1212/WNL.0000000000003592
12. Laurido-Soto, O., et al., Patient characteristics and outcome associations in AMPA receptor encephalitis. J Neurol, 2019. 266(2): p. 450–460. doi: 10.1007/s00415-018-9153-8.
13. Panzer, J.A. and R.C. Dale, Anti-AMPA receptor encephalitis: The family of glutamatergic autoencephalitides further expands. Neurology, 2015. 84(24): p. 2390–1. doi: 10.1212/WNL.0000000000001693